Insulin Degludec (Tresiba®, Novo Nordisk) for Diabetes

CTAF
February 12, 2016

The California Technology Assessment Forum (CTAF) held a public meeting in February 2016 to discuss the comparative effectiveness and value of a drug for patients with diabetes (type 1 and type 2). The diabetes drug, insulin degludec (Tresiba®, Novo Nordisk), is a long-acting basal insulin that patients inject once per day.

Key Dates

Associated Materials

10/13/2015

11/19/2015

12/18/2015

Research protocol posted to Open Science Framework: https://osf.io/7awvd/


12/21/2015

12/21/2015

01/25/2016

ICER’s response to public comments received on the draft report and voting questions on insulin degludec for the treatment of diabetes.